Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Alvina D. Chu"'
Autor:
Norito Katoh, MD, PhD, Yukihiro Ohya, MD, PhD, Hiroyuki Murota, MD, PhD, Masanori Ikeda, MD, PhD, Xiaofei Hu, PhD, Kimitoshi Ikeda, PhD, John Liu, MD, MS, Takuya Sasaki, Alvina D. Chu, MD, Henrique D. Teixeira, PhD, MBA, Hidehisa Saeki, MD, PhD
Publikováno v:
JAAD International, Vol 6, Iss , Pp 27-36 (2022)
Background: Systemic atopic dermatitis treatments that have acceptable safety are needed. Objective: To evaluate the safety of the oral Janus kinase inhibitor upadacitinib in combination with topical corticosteroids (TCSs) for the treatment of atopic
Externí odkaz:
https://doaj.org/article/3381acdcae8e440badf8a810bf6ba5e2
Autor:
Norito Katoh, Yukihiro Ohya, Hiroyuki Murota, Masanori Ikeda, Xiaofei Hu, Kimitoshi Ikeda, John Liu, Takuya Sasaki, Alvina D. Chu, Henrique D. Teixeira, Hidehisa Saeki
Publikováno v:
JAAD International
JAAD International, Vol 6, Iss, Pp 27-36 (2022)
JAAD International, Vol 6, Iss, Pp 27-36 (2022)
Background: Systemic atopic dermatitis treatments that have acceptable safety are needed. Objective: To evaluate the safety of the oral Janus kinase inhibitor upadacitinib in combination with topical corticosteroids (TCSs) for the treatment of atopic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dad6f61d4be10299f03e3bb56e5a83f
http://europepmc.org/articles/PMC8693619
http://europepmc.org/articles/PMC8693619
Autor:
Thomas Bieber, Alvina D. Chu, Barbara A. Hendrickson, Xiaofei Hu, Xiaohong Huang, Weily Soong, Jiewei Zeng, Marjolein S. de Bruin-Weller, Jonathan I. Silverberg, Thomas Werfel, Barry Ladizinski, Henrique D. Teixeira, Kenji Kabashima, Kristian Reich
Publikováno v:
The Lancet. 397:2169-2181
Systemic therapies are typically combined with topical corticosteroids for the management of moderate-to-severe atopic dermatitis. Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory potency for JAK1 than JAK2, JAK3, or tyros
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::043739cadf4685330cd6071d2ce88cac
https://doi.org/10.1016/s0140-6736(21)00589-4
https://doi.org/10.1016/s0140-6736(21)00589-4
Autor:
Emma Guttman-Yassky, Jacob P. Thyssen, Jonathan I. Silverberg, Kim A. Papp, Amy S. Paller, Stephan Weidinger, H. Chih-ho Hong, Barbara Hendrickson, Deanne Dilley, Allan R. Tenorio, Barry Ladizinski, Alvina D. Chu, John Liu, Alan D. Irvine
Publikováno v:
The Journal of allergy and clinical immunology. 151(1)
Upadacitinib is a selective reversible Janus kinase (JAK) inhibitor with established efficacy in moderate-to-severe atopic dermatitis (AD).We evaluated the safety of upadacitinib in patients with moderate-to-severe AD.Integrated safety data from the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f4756b93e656e695b07314d1f5b4149
https://pubmed.ncbi.nlm.nih.gov/36195170
https://pubmed.ncbi.nlm.nih.gov/36195170
Autor:
Andrea Everding, Alvina D. Chu, Tae-Hwan Kim, Yunxia Sui, X. Wang, In-Ho Song, Walter P. Maksymowych, Mitsumasa Kishimoto, Désirée van der Heijde, Filip Van den Bosch, Aileen L. Pangan, Atul Deodhar, Joachim Sieper
Publikováno v:
Lancet, 394(10214), 2108-2117. ELSEVIER SCIENCE INC
Background The JAK pathway is a potential therapeutic target in ankylosing spondylitis. This study assessed the efficacy and safety of upadacitinib, a selective JAK1 inhibitor, in patients with ankylosing spondylitis.Methods This multicentre, randomi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ed5a2d72c7d01b748f19ed6aa63fd00
https://doi.org/10.1016/s0140-6736(19)32534-6
https://doi.org/10.1016/s0140-6736(19)32534-6
Autor:
Alvina D. Chu, J. Liu, Sébastien Barbarot, Xiaofei Hu, Vimal H. Prajapati, Eric L. Simpson, Andrew Blauvelt, Tianshuang Wu, Barry Ladizinski, Antonio Costanzo, Marjolein S. de Bruin-Weller, Peter A. Lio, Henrique D. Teixeira, Kilian Eyerich
Publikováno v:
JAMA Dermatol
IMPORTANCE: Atopic dermatitis (AD) is a chronic, recurrent, inflammatory skin disease with an unmet need for treatments that provide rapid and high levels of skin clearance and itch improvement. OBJECTIVE: To assess the safety and efficacy of upadaci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8016220dcb89312a661b549622544e63
https://europepmc.org/articles/PMC8340015/
https://europepmc.org/articles/PMC8340015/
Autor:
Weily Soong, Barry Ladizinski, Jonathan I. Silverberg, David Rosmarin, Amy Gamelli, Kenji Kabashima, J. Liu, Thomas Bieber, Antonio Costanzo, Marjolein S. de Bruin-Weller, Kristian Reich, Alvina D. Chu, Charles Lynde, Jiewei Zeng
Publikováno v:
The Journal of allergy and clinical immunology. 149(3)
Background Primary (week 16) results from the ongoing phase 3, double-blind AD Up study (NCT03568318) demonstrate a positive benefit–risk profile for upadacitinib + topical corticosteroid (TCS) in patients with moderate-to-severe atopic dermatitis.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b37208840ac0e39d8fb0767b2cd0045
https://pubmed.ncbi.nlm.nih.gov/34403658
https://pubmed.ncbi.nlm.nih.gov/34403658
Autor:
Emma Guttman-Yassky, Y. Yang, Alvina D. Chu, Diamant Thaçi, Kim A. Papp, Amy S. Paller, Henrique D. Teixeira, Allan R. Tenorio, H. Chih ho Hong, Yihua Gu, Chia-Yu Chu, Brian M. Calimlim, Andrew Blauvelt, Alan D. Irvine, J. Liu, Norito Katoh, Eric L. Simpson, Xiaofei Hu, Aileen L. Pangan, Meng Liu
Publikováno v:
Lancet (London, England). 397(10290)
Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory potency for JAK1 than JAK2, JAK3, and tyrosine kinase 2. We aimed to assess the efficacy and safety of upadacitinib compared with placebo for the treatment of moderate-to-se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::492144b847c8ce679ac6c13620e80ef1
https://pubmed.ncbi.nlm.nih.gov/34090603
https://pubmed.ncbi.nlm.nih.gov/34090603
Autor:
Eric L. Simpson, Kim A. Papp, Andrew Blauvelt, Chia-Yu Chu, H. Chih-ho Hong, Norito Katoh, Brian M. Calimlim, Jacob P. Thyssen, Albert S. Chiou, Robert Bissonnette, Linda F. Stein Gold, Colleen Wegzyn, Xiaofei Hu, Meng Liu, John Liu, Allan R. Tenorio, Alvina D. Chu, Emma Guttman-Yassky
Publikováno v:
JAMA Dermatology. 158:404
Primary results from the Measure Up 1 and Measure Up 2 studies demonstrated upadacitinib efficacy and safety through 16 weeks in patients with atopic dermatitis. Longer-term outcomes remain unknown.To evaluate long-term (52 weeks) efficacy and safety
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12255c95346bdbd75246a2a2e5f5d25a
https://doi.org/10.1001/jamadermatol.2022.0029
https://doi.org/10.1001/jamadermatol.2022.0029
Autor:
Jiewei Zeng, W. Soong, Henrique D. Teixeira, Huang X, Bruin-Weller, Bieber T, Xiaofei Hu, Hendrickson B, Jonathan I. Silverberg, Thomas Werfel, Alvina D. Chu, Barry Ladizinski, Kristian Reich, Kenji Kabashima
Publikováno v:
SSRN Electronic Journal.
Background: Systemic therapies are typically combined with topical corticosteroids (TCS) in the management of moderate-to-severe atopic dermatitis (AD). Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor with greater inhibitory potency for JA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60b97b9ea479a21d65f63aef5eb9d2df
https://doi.org/10.2139/ssrn.3748383
https://doi.org/10.2139/ssrn.3748383